Trial
NCT06456567
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Vor Biopharma
Collaborators
—
Condition
Systemic Lupus Erythematosus
Intervention
Telitacicept
Why stopped
Sponsor business decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-09